To assess the association between use of sodium–glucose cotransporter 2 (SGLT2) inhibitors and retinal vein occlusion (RVO) using data from the National Health Insurance Service in South Korea.

We used an active comparator, new user design, and nationwide data from 2014 to 2017. Based on a 1:1 propensity score match, we included 47,369 new users of SGLT2 inhibitors and 47,369 users of other glucose-lowering drugs (oGLDs). In the matched sample, we used the Cox proportional hazards model to estimate hazard ratios (HRs) with 95% CIs for developing RVO. Based on the main outcome, exploratory subgroup analyses were undertaken.

During a follow-up of 2.57 years, the incidence rate of RVO was 2.19 and 1.79 per 1,000 person-years in patients treated with SGLT2 inhibitors and oGLDs, respectively. The new use of SGLT2 inhibitors was associated with an increased risk of RVO compared with oGLD use (HR 1.264 [95% CI 1.056, 1.513]). In the subgroup analyses, a significant interaction with SGLT2 inhibitors was observed for age and estimated glomerular filtration rate (eGFR); the HR for RVO was higher in patients aged ≥60 years and those with eGFR <60 mL/min/1.73 m² than in others.

In a matched cohort study, we found that SGLT2 inhibitors were associated with a significantly increased risk of RVO. Older patients and those with chronic kidney disease were at higher risk for RVO.

使用韩国国民健康保险服务的数据评估钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂的使用与视网膜静脉阻塞 (RVO) 之间的关联。

我们使用了主动比较器、新用户设计和 2014 年至 2017 年全国数据。基于 1:1 倾向评分匹配，我们纳入了 47,369 名 SGLT2 抑制剂的新用户和 47,369 名其他降糖药物 (oGLD) 的用户。在匹配样本中，我们使用 Cox 比例风险模型来估计开发 RVO 的风险比 (HR)，置信区间为 95%。根据主要结果，进行了探索性亚组分析。

在 2.57 年的随访期间，接受 SGLT2 抑制剂和 oGLD 治疗的患者中 RVO 的发生率分别为每 1000 人年 2.19 例和 1.79 例。与使用 oGLD 相比，新使用 SGLT2 抑制剂与 RVO 风险增加相关（HR 1.264 [95% CI 1.056, 1.513]）。在亚组分析中，观察到年龄和估计肾小球滤过率（eGFR）与 SGLT2 抑制剂存在显着的相互作用；年龄≥60 岁的患者和 eGFR <60 id=174>2 的患者的 RVO HR 高于其他患者。

在一项匹配队列研究中，我们发现 SGLT2 抑制剂与 RVO 风险显着增加相关。老年患者和患有慢性肾病的患者发生 RVO 的风险较高。